Allianz SE Reduces Position in DexCom, Inc. (NASDAQ:DXCM)

Allianz SE lessened its holdings in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 11.5% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 44,460 shares of the medical device company's stock after selling 5,756 shares during the quarter. Allianz SE's holdings in DexCom were worth $3,036,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of DXCM. Nia Impact Advisors LLC lifted its holdings in shares of DexCom by 1.4% in the fourth quarter. Nia Impact Advisors LLC now owns 9,850 shares of the medical device company's stock worth $766,000 after buying an additional 140 shares in the last quarter. Covestor Ltd grew its stake in DexCom by 15.6% during the fourth quarter. Covestor Ltd now owns 1,109 shares of the medical device company's stock valued at $86,000 after acquiring an additional 150 shares in the last quarter. Wedbush Securities Inc. increased its holdings in DexCom by 1.2% during the 1st quarter. Wedbush Securities Inc. now owns 13,168 shares of the medical device company's stock worth $899,000 after acquiring an additional 157 shares during the period. Argonautica Private Wealth Management Inc. lifted its stake in DexCom by 3.2% in the 1st quarter. Argonautica Private Wealth Management Inc. now owns 5,958 shares of the medical device company's stock worth $407,000 after purchasing an additional 182 shares in the last quarter. Finally, Personal CFO Solutions LLC lifted its stake in DexCom by 7.3% in the 1st quarter. Personal CFO Solutions LLC now owns 3,446 shares of the medical device company's stock worth $235,000 after purchasing an additional 234 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company's stock.

Insiders Place Their Bets

In related news, EVP Sadie Stern sold 6,184 shares of the firm's stock in a transaction on Tuesday, May 27th. The stock was sold at an average price of $85.11, for a total value of $526,320.24. Following the completion of the sale, the executive vice president owned 109,621 shares of the company's stock, valued at $9,329,843.31. This trade represents a 5.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Mark G. Foletta sold 2,750 shares of the business's stock in a transaction on Monday, June 16th. The shares were sold at an average price of $83.13, for a total transaction of $228,607.50. Following the transaction, the director directly owned 56,621 shares in the company, valued at approximately $4,706,903.73. The trade was a 4.63% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 28,656 shares of company stock valued at $2,412,191 over the last three months. 0.32% of the stock is currently owned by corporate insiders.

DexCom Trading Down 1.8%

NASDAQ DXCM opened at $79.28 on Monday. The company has a current ratio of 1.52, a quick ratio of 1.35 and a debt-to-equity ratio of 0.48. DexCom, Inc. has a 1-year low of $57.52 and a 1-year high of $93.25. The stock has a 50-day moving average of $84.57 and a 200-day moving average of $80.60. The firm has a market cap of $31.09 billion, a PE ratio of 55.06, a price-to-earnings-growth ratio of 1.66 and a beta of 1.43.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The medical device company reported $0.48 EPS for the quarter, beating the consensus estimate of $0.45 by $0.03. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The firm had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. During the same period in the prior year, the firm posted $0.43 earnings per share. The company's quarterly revenue was up 15.2% compared to the same quarter last year. As a group, sell-side analysts forecast that DexCom, Inc. will post 2.03 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. Citigroup reaffirmed a "buy" rating and issued a $102.00 price target (up previously from $82.00) on shares of DexCom in a report on Thursday, May 22nd. Wall Street Zen upgraded DexCom from a "buy" rating to a "strong-buy" rating in a research report on Saturday. Barclays upped their target price on DexCom from $93.00 to $98.00 and gave the stock an "equal weight" rating in a research note on Wednesday, July 30th. Robert W. Baird dropped their price target on DexCom from $115.00 to $105.00 and set an "outperform" rating for the company in a research report on Friday, May 2nd. Finally, Mizuho boosted their price objective on DexCom from $95.00 to $100.00 and gave the stock an "outperform" rating in a report on Wednesday, July 16th. Four analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have issued a strong buy rating to the company's stock. According to MarketBeat, DexCom has a consensus rating of "Buy" and an average target price of $99.89.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.